The DOI matches its Crossref record; 416 of the 416 references it cites were found in a registry or an index.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Abstract
Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationTamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Scottish Intercollegiate Guidelines Network
Twaddle, S., & Qureshi, S. (2005) · Evidence-based Healthcare and Public Health · doi:10.1016/j.ehbc.2005.09.008 · Cited by 4,084
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., & Ederer, F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281901 · Cited by 3,229
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Levin, B., Lieberman, D. A., McFarland, B., Andrews, K. S., Brooks, D., Bond, J., Dash, C., Giardiello, F. M., Glick, S., Johnson, D., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.002 · Cited by 2,990
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
Hardcastle, J. D., Chamberlain, J. O., Robinson, M. H., Moss, S. M., Amar, S. S., Balfour, T. W., James, P. D., & Mangham, C. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03386-7 · Cited by 2,793
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · cited 1×
“immunomagnetic capture and staining methods (227).”
MethodRandomised study of screening for colorectal cancer with faecal-occult-blood test
Kronborg, O., Fenger, C., Olsen, J., Jørgensen, O. D., & Søndergaard, O. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03430-7 · Cited by 2,501
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Self-citationLynch, H. T., & de la Chapelle, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012242 · Cited by 2,203
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.594 · Cited by 1,929
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Levin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. S., Dash, C., Giardiello, F. M., Glick, S., Levin, T. R., et al. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0018 · Cited by 1,801
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16044-3 · Cited by 1,697
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
Self-citationASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Self-citationCatalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35233-3 · Cited by 1,592
American Cancer Society Guidelines for the Early Detection of Cancer
Smith, R. A., Cokkinides, V., von Eschenbach, A. C., Levin, B., Cohen, C., Runowicz, C. D., Sener, S., Saslow, D., & Eyre, H. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.8 · Cited by 1,588
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer
Mandel, J. S., Church, T. R., Bond, J. H., Ederer, F., Geisser, M. S., Mongin, S. J., Snover, D. C., & Schuman, L. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432203 · Cited by 1,423
Clinical practice guidelines : directions for a new program
Field, M. J., & Lohr, K. N. (1990) · Cited by 1,415
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I. J., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,379
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.270.7.860 · Cited by 1,266
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,242
Prognostic Factors in Prostate Cancer: College of American Pathologists Consensus Statement 1999
Bostwick, D. G., Grignon, D. J., Hammond, M. E. H., Amin, M. B., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R. S., Miller, D. S., Montironi, R., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0995-pfipc · Cited by 1,239
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Prognostic Factors in Colorectal Cancer: College of American Pathologists Consensus Statement 1999
Compton, C. C., Fielding, L. P., Burgart, L. J., Conley, B., Cooper, H. S., Hamilton, S. R., Hammond, M. E. H., Henson, D. E., Hutter, R. V. P., Nagle, R. B., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0979-pficc · Cited by 1,230
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps
Maisonneuve, P., Botteri, E., & Lowenfels, A. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.039 · Cited by 1,183
Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Self-citationGoldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
A protein interaction network for pluripotency of embryonic stem cells
Wang, J., Rao, S., Chu, J., Shen, X., Levasseur, D. N., Theunissen, T. W., & Orkin, S. H. (2006) · Nature · doi:10.1038/nature05284 · Cited by 1,099
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Adjuvant Therapy for Patients With Colon and Rectal Cancer
(1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450110090034 · Cited by 1,086
Draisma, G., Boer, R., Otto, S. J., van der Cruijsen, I. W., Damhuis, R. A. M., Schroder, F. H., & de Koning, H. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.868 · Cited by 1,071
Methods in molecular medicine.
Craig, R. K. (1987) · BMJ · doi:10.1136/bmj.295.6599.646 · Cited by 1,057
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
Partin, A. W., Mangold, L. A., Lamm, D. M., Walsh, P. C., Epstein, J. I., & Pearson, J. D. (2001) · Urology · doi:10.1016/s0090-4295(01)01441-8 · Cited by 1,038
Mead, G. M., Stenning, S. P., Cook, P. A., Fosså, S. D., Horwich, A., Kaye, S. B., Oliver, R. T. D., deMulder, P., deWit, R., Stoter, G., et al. (1997) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1,033
McCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999
Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., Ruby, S. G., O'Malley, F., Simpson, J. F., Connolly, J. L., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
Self-citationBurke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
The CA 125 tumour-associated antigen: a review of the literature
Jacobs, I., & Bast, R. C. (1989) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136832 · Cited by 955
Self-citationGoldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm271 · Cited by 944
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Self-citationStenman, U., Leinonen, J., Alfthan, H. V., et al. (1991) · PubMed · Cited by 930
Self-citationBraun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C. R. M., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420801 · Cited by 923
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
Lilja, H., Christensson, A., Dahlén, U., Matikainen, M. T., Nilsson, O., Pettersson, K., & Lövgren, T. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.9.1618 · Cited by 910
Self-citationLi, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., & Chan, D. W. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1296 · Cited by 893
Self-citationBosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Self-citationKirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Smith, R. A., von Eschenbach, A. C., Wender, R., Levin, B., Byers, T., Rothenberger, D., Brooks, D., Creasman, W., Cohen, C., Runowicz, C., et al. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.38 · Cited by 821
Bernie, T., Les, I., Paul, G., Jan, K., David, W., & Chris, S. (1998) · BMJ · doi:10.1136/bmj.317.7158.559 · Cited by 811
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.1993.03510070082041 · Cited by 807
Fecal DNA versus Fecal Occult Blood for Colorectal-Cancer Screening in an Average-Risk Population
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Turnbull, B. A., & Ross, M. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033403 · Cited by 803
Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?
Duffy, M. J. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.624 · Cited by 794
Self-citationCooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C., & Kidd, D. D. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40211-4 · Cited by 767
D'Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004) · JAMA · doi:10.1001/jama.292.7.821 · Cited by 767
Benson, M. C., Whang, I. S., Pantuck, A. J., Ring, K. S., Kaplan, S. A., Olsson, C. A., & Cooner, W. H. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37393-7 · Cited by 763
Bardou, V.-J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.099 · Cited by 752
(2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.189 · Cited by 751
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
Self-citationScreening for colorectal cancer using the faecal occult blood test, Hemoccult
Hewitson, P., Glasziou, P. P., Irwig, L., Towler, B., & Watson, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001216.pub2 · Cited by 742
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Wheeler, T. M., & Scardino, P. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1499 · Cited by 741
Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy
D'Amico, A. V., Chen, M.-H., Roehl, K. A., & Catalona, W. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032975 · Cited by 740
POSSIBLE CARCINOMA-IN-SITU OF THE TESTIS
Skakkebæk, N. (1972) · The Lancet · doi:10.1016/s0140-6736(72)91909-5 · Cited by 739
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
The Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735
Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population
Pisani, P., Bray, F., & Parkin, D. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.1571 · Cited by 730
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Hellström, I., Raycraft, J., Hayden-Ledbetter, M. S., Ledbetter, J. A., Schummer, M., McIntosh, M. W., Drescher, C. W., Urban, N. D., & Hellström, K. E. (2003) · PubMed · Cited by 711
DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer
Hessels, D., Klein Gunnewiek, J. M. T., van Oort, I., Karthaus, H. F. M., van Leenders, G. J. L., van Balken, B., Kiemeney, L. A., Witjes, J. A., & Schalken, J. A. (2003) · European Urology · doi:10.1016/s0302-2838(03)00201-x · Cited by 704
Identification of ras Oncogene Mutations in the Stool of Patients with Curable Colorectal Tumors
Sidransky, D., Tokino, T., Hamilton, S. R., Kinzler, K. W., Levin, B., Frost, P., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1566048 · Cited by 698
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.576 · Cited by 697
Moore, R. G., Brown, A. K., Miller, M. C., Skates, S., Allard, W. J., Verch, T., Steinhoff, M., Messerlian, G., DiSilvestro, P., Granai, C. O., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.017 · Cited by 695
Self-citationSequence and structural analysis of BTB domain proteins
Stogios, P. J., Downs, G. S., Jauhal, J. J., Nandra, S. K., & Privé, G. G. (2005) · Genome Biology · doi:10.1186/gb-2005-6-10-r82 · Cited by 694
Pten Dose Dictates Cancer Progression in the Prostate
Trotman, L. C., Niki, M., Dotan, Z. A., Koutcher, J. A., Di Cristofano, A., Xiao, A., Khoo, A. S., Roy-Burman, P., Greenberg, N. M., Dyke, T. V., et al. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000059 · Cited by 676
Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Histological Typing of Ovarian Tumours
Scully, R. E. (1999) · Springer eBooks · doi:10.1007/978-3-642-58564-7 · Cited by 654
Biological Variation: From Principles to Practice
Fraser, C. G. (2001) · Cited by 653
Renehan, A. G., Egger, M., Saunders, M. P., & O'Dwyer, S. T. (2002) · BMJ · doi:10.1136/bmj.324.7341.813 · Cited by 651
UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years
Peto, R., Boreham, J., Clarke, M., Davies, C., & Beral, V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02277-7 · Cited by 648
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.
Looijenga, L. H. J., Stoop, H., de Leeuw, H. P. J. C., Brazao, C. A. D. G., Gillis, A., van Roozendaal, K. E. P., van Zoelen, E. J. J., Weber, R. F. A., Wolffenbuttel, K. P., van Dekken, H., et al. (2003) · PubMed · Cited by 639
Self-citationAmerican Cancer Society Guidelines for the Early Detection of Cancer, 2006
Smith, R. A., Cokkinides, V., & Eyre, H. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.1.11 · Cited by 639
Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers
Xu, Y. (1998) · JAMA · doi:10.1001/jama.280.8.719 · Cited by 637
Gianni, L., Zambetti, M., Clark, K., Baker, J., Cronin, M., Wu, J., Mariani, G., Rodriguez, J., Carcangiu, M., Watson, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0818 · Cited by 626
A Comparison of Fecal Occult-Blood Tests for Colorectal-Cancer Screening
Allison, J. E., Tekawa, I. S., Ransom, L. J., & Adrain, A. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601183340304 · Cited by 622
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Sparano, J. A., & Paik, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1068 · Cited by 617
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Increasing Incidence of Testicular Cancer Worldwide: A Review
HUYGHE, E., MATSUDA, T., & THONNEAU, P. (2003) · Journal of Urology · doi:10.1097/01.ju.0000053866.68623.da · Cited by 605
Wooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
Winawer, S. J., Schottenfeld, D., & Flehinger, B. J. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.4.243 · Cited by 599
American Joint Committee on Cancer prognostic factors consensus conference: Colorectal working group
Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., & Fielding, L. P. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · Cited by 599
Screening for Colorectal Cancer: Recommendation and Rationale
U.S. Preventive Services Task Force* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-2-200207160-00014 · Cited by 597
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596
Self-citationOvarian Cancer: Screening, Treatment, and Follow-up
Seltzer, V. (1995) · JAMA · doi:10.1001/jama.1995.03520300065039 · Cited by 580
Desch, C. E., Benson, A. B., Somerfield, M. R., Flynn, P. J., Krause, C., Loprinzi, C. L., Minsky, B. D., Pfister, D. G., Virgo, K. S., & Petrelli, N. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0063 · Cited by 559
Carter, H. B., Ferrucci, L., Kettermann, A., Landis, P., Wright, E. J., Epstein, J. I., Trock, B. J., & Metter, E. J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj410 · Cited by 556
The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin
Seidman, J. D., Horkayne-Szakaly, I., Haiba, M., Boice, C. R., Kurman, R. J., & Ronnett, B. M. (2004) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000101080.35393.16 · Cited by 554
STAMEY, T. A., CALDWELL, M., McNEAL, J. E., NOLLEY, R., HEMENEZ, M., & DOWNS, J. (2004) · Journal of Urology · doi:10.1097/01.ju.0000139993.51181.5d · Cited by 545
Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., Halberg, F., Somerfield, M. R., & Davidson, N. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8575 · Cited by 535
Ahlquist, D. A., Skoletsky, J. E., Boynton, K. A., Harrington, J. J., Mahoney, D. W., Pierceall, W. E., Thibodeau, S. N., & Shuber, A. P. (2000) · Gastroenterology · doi:10.1053/gast.2000.19580 · Cited by 533
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Hernández, J., & Thompson, I. M. (2004) · Cancer · doi:10.1002/cncr.20480 · Cited by 527
Schmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S. D., Skakkebaek, N. E., de Wit, R., Fizazi, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh301 · Cited by 510
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Self-citationScreening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-3-200808050-00008 · Cited by 505
Habel, L. A., Shak, S., Jacobs, M. K., Capra, A., Alexander, C., Pho, M., Baker, J., Walker, M., Watson, D., Hackett, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1412 · Cited by 484
Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
Kim, J.-H. (2002) · JAMA · doi:10.1001/jama.287.13.1671 · Cited by 480
Press, M. F., Hung, G., Godolphin, W. J., & Slamon, D. (1994) · PubMed · Cited by 478
FLETCHER, R. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-1-66 · Cited by 473
Clinical Application of the 70-Gene Profile: The MINDACT Trial
Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S., & Piccart-Gebhart, M. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3222 · Cited by 464
Sotiriou, C., & Piccart, M. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2173 · Cited by 461
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
Duffy, M. J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059832 · Cited by 460
Self-citationPopat, S., Matakidou, A., & Houlston, R. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.064 · Cited by 449
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
Yaziji, H. (2004) · JAMA · doi:10.1001/jama.291.16.1972 · Cited by 438
Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J. F., Selbmann, H.-K., Graeff, H., & Schmitt, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.913 · Cited by 434
Self-citationMaruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zöchbauer‐Müller, S., Farinas, A. J., Vakar‐Lopez, F., Minna, J. D., Sagalowsky, A. I., et al. (2001) · PubMed · Cited by 422
Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal Cancer
Goldstein, M. J., & Mitchell, E. P. (2005) · Cancer Investigation · doi:10.1081/cnv-58878 · Cited by 419
AMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66452-x · Cited by 408
U.S. Preventive Services Task Force* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00011 · Cited by 405
Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., & Allegra, C. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2640 · Cited by 405
Serum alpha-fetoprotein, albumin, and gamma-G-globulin in the human conceptus.
Gitlin, D., & Boesman, M. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105486 · Cited by 404
Schmid, H.-P., McNeal, J. E., & Stamey, T. A. (1993) · Cancer · doi:10.1002/1097-0142(19930315)71:6<2031::aid-cncr2820710618>3.0.co;2-q · Cited by 401
Samowitz, W. S., Curtin, K., Ma, K., Schaffer, D., Coleman, L. W., Leppert, M., & Slattery, M. L. (2001) · PubMed · Cited by 401
CA 125: The past and the Future
Bast, R. C., Xu, F.-J., Yu, Y.-H., Barnhill, S., Zhang, Z., & Mills, G. B. (1998) · The International Journal of Biological Markers · doi:10.1177/172460089801300402 · Cited by 397
Self-citationFollow-up of patients with curatively resected colorectal cancer: a practice guideline
Figueredo, A., Rumble, R. B., Maroun, J., Earle, C. C., Cummings, B., McLeod, R., Zuraw, L., Zwaal, C., & the members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2003) · BMC Cancer · doi:10.1186/1471-2407-3-26 · Cited by 392
Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Perspectives on alkaline phosphatase isoenzymes
Fishman, W. H. (1974) · The American Journal of Medicine · doi:10.1016/0002-9343(74)90631-7 · Cited by 390
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.104 · Cited by 389
Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X.-L., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203598 · Cited by 384
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Rustin, G. J. S., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I., et al. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh081 · Cited by 378
Clinical utility of biochemical markers in colorectal cancer
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R., Nilsson, O., Sturgeon, C., & Topolcan, O. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00811-0 · Cited by 374
Self-citationAllison, J. E., Sakoda, L. C., Levin, T. R., Tucker, J. P., Tekawa, I. S., Cuff, T., Pauly, M. P., Shlager, L., Palitz, A. M., Zhao, W. K., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm150 · Cited by 372
Gennari, A., Sormani, M. P., Pronzato, P., Puntoni, M., Colozza, M., Pfeffer, U., & Bruzzi, P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm252 · Cited by 371
Maruyama, R., Toyooka, S., Toyooka, K. O., Virmani, A. K., Zöchbauer‐Müller, S., Farinas, A. J., Minna, J. D., McConnell, J. D., Frenkel, E. P., & Gazdar, A. F. (2002) · PubMed · Cited by 370
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2843 · Cited by 353
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Harris, R., & Lohr, K. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00014 · Cited by 348
AMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · The Journal of Urology · doi:10.1097/00005392-200104000-00020 · Cited by 348
AGA technical review on hereditary colorectal cancer and genetic testing
(2001) · Gastroenterology · doi:10.1053/gast.2001.25581 · Cited by 347
Nelson, H. D., Huffman, L. H., Fu, R., & Harris, E. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00012 · Cited by 346
Follow-Up After Curative Resection of Colorectal Cancer: A Meta-Analysis
Tjandra, J. J., & Chan, M. K. Y. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-9030-5 · Cited by 342
Kim, G. P., Colangelo, L. H., Wieand, H. S., Paik, S., Kirsch, I. R., Wolmark, N., & Allegra, C. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8172 · Cited by 342
Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A. F., & Yeatman, T. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1405-2 · Cited by 341
Trends in the incidence of testicular germ cell tumors in the United States
McGlynn, K. A., Devesa, S. S., Sigurdson, A. J., Brown, L. M., Tsao, L., & Tarone, R. E. (2003) · Cancer · doi:10.1002/cncr.11054 · Cited by 338
Lysophospholipids Are Potential Biomarkers of Ovarian Cancer
Sutphen, R., Xu, Y., Wilbanks, G. D., Fiorica, J., Grendys, E. C., LaPolla, J. P., Arango, H., Hoffman, M. S., Martino, M., Wakeley, K., et al. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.1185.13.7 · Cited by 338
Detecting Colorectal Cancer in Stool With the Use of Multiple Genetic Targets
Dong, S. M., Traverso, G., Johnson, C., Geng, L., Favis, R., Boynton, K., Hibi, K., Goodman, S. N., D'Allessio, M., Paty, P., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.11.858 · Cited by 337
Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Sölétormos, G., et al. (2005) · Tumor Biology · doi:10.1159/000089260 · Cited by 334
Self-citationPunglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., & Kuntz, K. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021659 · Cited by 326
Elledge, R. M., Green, S., Pugh, R., Allred, D. C., Clark, G. M., Hill, J., Ravdin, P., Martino, S., & Osborne, C. K. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2<111::aid-ijc2>3.0.co;2-w · Cited by 325
Follow-Up of Patients with Colorectal Cancer A Meta-Analysis
Bruinvels, D. J., Stiggelbout, A. M., Kievit, J., van Houwellngen, H. C., F. Habbema, J. D., & van de Velde, C. J. H. (1994) · Annals of Surgery · doi:10.1097/00000658-199402000-00009 · Cited by 322
Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology
Mok, S. C., Chao, J., Skates, S., Wong, K.-K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., & Cramer, D. W. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1458 · Cited by 320
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
DUFFY, M. J., BONFRER, J. M., KULPA, J., RUSTIN, G. J. S., SOLETORMOS, G., TORRE, G. C., TUXEN, M. K., & ZWIRNER, M. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00130.x · Cited by 317
Self-citationBartsch, G., Horninger, W., Klocker, H., Reissigl, A., Oberaigner, W., Schönitzer, D., Severi, G., Robertson, C., & Boyle, P. (2001) · Urology · doi:10.1016/s0090-4295(01)01264-x · Cited by 315
Guidelines on Testicular Cancer
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Horwich, A., Klepp, O., Laguna, M. P., & Pizzocaro, G. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.019 · Cited by 314
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
Pharoah, P. D. P., Day, N. E., & Caldas, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690628 · Cited by 308
The DCC Protein and Prognosis in Colorectal Cancer
Shibata, D., Reale, M. A., Lavin, P., Silverman, M., Fearon, E. R., Steele, G., Jessup, J. M., Loda, M., & Summerhayes, I. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612053352303 · Cited by 308
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., & Piccart, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi352 · Cited by 307
Predicting the Presence and Side of Extracapsular Extension: A Nomogram for Staging Prostate Cancer
OHORI, M., KATTAN, M. W., KOH, H., MARU, N., SLAWIN, K. M., SHARIAT, S., MURAMOTO, M., REUTER, V. E., WHEELER, T. M., & SCARDINO, P. T. (2004) · Journal of Urology · doi:10.1097/01.ju.0000121693.05077.3d · Cited by 297
Human chorionic gonadotropin in cancer
Stenman, U.-H., Alfthan, H., & Hotakainen, K. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.008 · Cited by 294
Self-citation
Cited by
Practice Parameters for the Management of Rectal Cancer (Revised)
Monson, J. R. T., Weiser, M. R., Buie, W. D., Chang, G. J., Rafferty, J. F., Buie, W. D., Rafferty, J., Guillem, J., Boushey, R., Chang, G., et al. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31828cb66c · Cited by 563
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Self-citationEvidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481
Broza, Y. Y., Zhou, X., Yuan, M., Qu, D., Zheng, Y., Vishinkin, R., Khatib, M., Wu, W., & Haick, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00437 · Cited by 461
Metadata
- Authors
- Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Sölétormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., & Diamandis, E. P.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-01
- Volume
- 54
- Issue
- 12
- Pages
- e11-e79
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2099052946
- Cited by
- 1,129
- References
- 416
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.